Health-care companies fell as traders rotated out of the defensive sector.

Xenon shares tumbled after the drug developer said it was temporarily halting enrollment in a late-stage clinical trial on patients with major depressive disorder and bipolar depression.

Novo shares were more or less flat as Canadian regulators approved a generic version of its Ozempic diabetes and weight-loss drug from Swiss pharmaceutical manufacturer Sandoz.